ACRX AcelRx Pharmaceuticals, Inc.

2.70
+0  (2%)
Previous Close 2.65
Open 2.65
Price To book 0.00
Market Cap 122.41M
Shares 45,336,000
Volume 119,223
Short Ratio 18.78
Av. Daily Volume 204,363

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
PDUFA date October 12, 2017. Advisory Committee meeting planned.
ARX-04 (SAP303)
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. Additional clinical trial initiated September 2016.
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery

Latest News

  1. AcelRx Pharmaceuticals Reports Publication of Manuscripts Analyzing IV, Transdermal and Sublingual Patient-Controlled Analgesia Systems
  2. ETFs with exposure to AcelRx Pharmaceuticals, Inc. : April 11, 2017
  3. AcelRx Pharmaceuticals Presenting Comprehensive DSUVIA Clinical Trial Results at ASRA's Annual Regional Anesthesiology and Acute Pain Medicine Meeting
  4. Edited Transcript of ACRX earnings conference call or presentation 2-Mar-17 9:30pm GMT
  5. European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30 mcg Tablet (ARX-04) for Moderate-to-Severe Acute Pain
  6. ETFs with exposure to AcelRx Pharmaceuticals, Inc. : March 27, 2017
  7. AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  8. AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March and April
  9. AcelRx Pharmaceuticals, Inc. to Present at The MicroCap Conference on April 4th in New York City at the Essex House
  10. AcelRx Pharmaceuticals Presents Efficacy and Pharmacokinetics of DSUVIA™ at Upcoming Congresses
  11. AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  12. AcelRx Pharmaceuticals reports 4Q loss
  13. AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results
  14. AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in March
  15. AcelRx Pharmaceuticals' New Drug Application for DSUVIA Accepted for Filing with PDUFA Date of October 12, 2017
  16. AcelRx Pharmaceuticals to Hold Annual 2016 Financial Results Conference Call and Webcast on Thursday, March 2nd, 2017
  17. AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
  18. AcelRx Pharmaceuticals Presentation at JAB Burn Symposium Highlights Potential of DSUVIA™ for Use in Burn Victims with Moderate-to-Severe Acute Pain
  19. AcelRx Pharmaceuticals to Participate at Four Upcoming Investor Events in February
  20. AcelRx Pharmaceuticals (ACRX) in Focus: Stock Rises 5.3%